Advent-backed BioDuro, a global life sciences research company, agreed to acquire Sundia MediTech, a pre-clinical contract research and manufacturing organization. Financial terms were not disclosed. "We are greatly looking forward to this new venture with BioDuro combining our discovery, R&D and CMC expertise to provide customers with a highly competitive and innovative end-to-end CRDMO solution. As a service provider, this kind of productivity creates a ripple effect to the benefit of the whole biopharma sector. It enables us to accelerate timelines for hundreds of companies and to help bring medicines to patients faster for countless programs," Cathy Yen, BioDuro Director.